Pomerantz Law Firm Launches Investigation into Capricor Therapeutics Investors' Claims

Investor Alert: Pomerantz Law Firm Investigates Capricor Therapeutics

Pomerantz LLP, a distinguished law firm known for its expertise in corporate and securities class litigation, is investigating claims from investors of Capricor Therapeutics, Inc. (NASDAQ: CAPR). This inquiry follows the company's recent troubling disclosures pertaining to their investigational drug, deramiocel.

The Context of Investigation

On May 5, 2025, Capricor announced it had received feedback from the U.S. Food and Drug Administration (FDA) regarding their Biologics License Application for deramiocel. The FDA’s indication of an upcoming advisory committee meeting was initially seen as a positive development. However, this optimism was short-lived.

Just a day later, on May 6, Capricor's stock experienced a significant decline, plummeting by $3.00 per share, or 29.13%, closing at $7.30 per share. This unexpected drop raised concerns among investors about the company’s business practices and the reliability of their communications regarding the drug’s potential.

Regulatory Challenges and Market Reaction

The situation escalated yet again when reports emerged on June 20, 2025, suggesting that the head of the FDA unit responsible for evaluating deramiocel had canceled the advisory committee meeting due to rising doubts about the drug's efficacy and safety. This announcement sent shockwaves through the market, resulting in another substantial drop of 30.82% in Capricor’s stock price, which fell $3.68 per share to close at $8.26.

Investors who felt misled by the company’s announcements may have grounds for litigation over potential securities fraud or other unlawful practices. Pomerantz law firm is committed to uncovering the truth behind these developments and urging affected shareholders to reach out.

Capricor's Commitment and Corporate Governance

As an entity focused on innovating treatments for rare diseases, Capricor's challenges are not just stock market figures; they impact real patients suffering from Duchenne muscular dystrophy (DMD) cardiomyopathy. With a headline product like deramiocel at stake, the scrutiny on their corporate governance and communication strategies is more critical than ever.

Pomerantz LLP, with a robust history of class action litigation, emphasizes the importance of maintaining integrity in business practices. Founded by Abraham L. Pomerantz, a pioneer in the field, the firm stands at the forefront of advocating for investors’ rights in instances of corporate misconduct.

The Path Forward

Affected investors are encouraged to contact Pomerantz LLP’s Danielle Peyton for more information on how to join in on this investigation. Potential claimants can reach out via email or phone to understand their rights and options moving forward.

This situation underscores the volatile nature of biotechnology investments and the critical importance of transparency from companies developing life-altering treatments. As investigations unfold, investors will be watching closely to see how Capricor navigates this tumultuous period while remaining committed to delivering on its promises to patients and stakeholders alike.

In the world of securities, yesterday’s news can turn into today’s turbulence, leaving investors yearning for answers and accountability. Pomerantz LLP is poised to provide those answers as they explore these pressing claims against Capricor Therapeutics.